GET WAIVED NOW!

Facts & Figures

Fighting the battle on opioid use disorder nationwide

About

MISSION
Regional hospital systems, through the Medication Assisted Treatment and Emergency Referrals (MATTERS) network are partnering with community-based substance use treatment programs to reduce inappropriate controlled substance prescribing, increase access to medication assisted treatment (MAT), and provide rapid access to substance use treatment programs.

VISION

To aid our shared patients in initiating and continuing successful opioid and overall substance use disorder treatment.
To reduce morbidity and mortality associated with opiate and substance use disorder.
To provide a best practice model for Hospital and Emergency Department Initiated Buprenorphine Programs that others can emulate.
To provide the same high level of care to patients suffering from opiate use disorder that we would for any other emergency medical condition.

MAP LEGEND:
Blue – Preliminary Involvement
Black – Presentation

VALUES

Hospital Partners will follow these values:

We will prescribe buprenorphine for patients when appropriate based on our guidelines.
We will not automatically disqualify patients from receiving buprenorphine if they engage in polysubstance abuse (especially benzodiazepines and/or alcohol).
We will refer patients to the most appropriate follow up possible based on their unique needs.
We will inform patients of the referral program’s expectations.
We will continuously evaluate our program and share our lessons learned with others.

Community-based substance abuse treatment programs that embody these values:

They will accept and work with patients regardless of insurance status.
They will accept patients who have not been prescribed buprenorphine or MAT in the past.
They will offer timely appointments to patients referred from the hospital and emergency department.
They will accept referred patients even if previously discharged from a treatment program.
They will not automatically disqualify patients from receiving medication assisted treatment if they engage in polysubstance abuse (especially benzodiazepines and/or alcohol).
They will not place undue financial burden on the patient.
They will provide care that is culturally appropriate for the target population of patients with substance use disorder.
They will provide feedback referring providers regarding the disposition of referred patients to improve processes.

Affiliate Networks

Sample Process

Evidence

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527523/

https://www.chcf.org/wp-content/uploads/2017/12/PDF-EDMATOpioidProtocols.pdf

https://www.acep.org/globalassets/uploads/uploaded-files/acep/clinical-and-practice-management/resources/mental-health-and-substance-abuse/initiating-opioid-treatment-in-the-emergency-department-ed-faqs.pdf

News

Latest News

MATTERS Network

April 8, 2019

NYS Department of Health Leads Multistate Effort to Call on the Federal Government to Improve Access to Buprenorphine to Treat Opioid Disorder

health.ny.gov April 8, 2019 Coalition of 22 States and Territories Calls for Changes to Outdated Federal Policy Calls for Increasing the Cap on How Many Patients can be Treated and…

MATTERSNetAdmin

All News

From Twitter

MATTERS NetworkFollow

Retweet on Twitter MATTERS Network Retweeted

R. Lamartiniere, MD @rlamartini·

16 Apr

@matters_network @JMPerroneMD @LeoBeletsky @AnnalsofEM @highlandherring @LNelsonMD @PA_ACEP Sounds like a very good setup you have there. That is an uncommon scenario nationwide as buprenorphine MAT is still hard to obtain in many areas.

Reply on Twitter 1118113826824773632 Retweet on Twitter 11181138268247736321 Like on Twitter 11181138268247736321 Twitter 1118113826824773632

Retweet on Twitter MATTERS Network Retweeted

Jeanmarie Perrone MD @JMPerroneMD·

11 Jan

Buprenorphine for opioid withdrawal-essentially the same pathway as induction. Don’t let patients suffer with zofran and clonidine when buprenorphine will mitigate withdrawal symptoms and give time to consider treatment +recovery @AnnalsofEM @highlandherring @LNelsonMD @PA_ACEP

Reply on Twitter 1083580531470671873 Retweet on Twitter 108358053147067187356 Like on Twitter 1083580531470671873158 Twitter 1083580531470671873

Retweet on Twitter MATTERS Network Retweeted

Jonathan Giftos, MD 🌹🗽@JonGiftosMD·

17 Apr

Excellent overview of the Indivior indictment by ⁦⁦@alisonknopf⁩ for ⁦@Filtermag_org⁩ with important quote by ⁦@LeoBeletsky⁩:

“This is not an indictment of the medication, but of the pharmaceutical industry.” https://t.co/p7RH5FYQFM

Reply on Twitter 1118317037552590848 Retweet on Twitter 111831703755259084818 Like on Twitter 111831703755259084840 Twitter 1118317037552590848